NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery.
Solid track record and good value.
Share Price & News
How has NuVasive's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NK8's share price has been volatile over the past 3 months.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: NK8 underperformed the German Medical Equipment industry which returned 33.7% over the past year.
Return vs Market: NK8 matched the German Market which returned 4.4% over the past year.
Price Volatility Vs. Market
How volatile is NuVasive's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is NuVasive undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NK8 (€55) is trading below our estimate of fair value (€68.94)
Significantly Below Fair Value: NK8 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NK8 is poor value based on its PE Ratio (52.2x) compared to the Medical Equipment industry average (49.6x).
PE vs Market: NK8 is poor value based on its PE Ratio (52.2x) compared to the German market (20.1x).
Price to Earnings Growth Ratio
PEG Ratio: NK8 is good value based on its PEG Ratio (0.9x)
Price to Book Ratio
PB vs Industry: NK8 is good value based on its PB Ratio (4x) compared to the DE Medical Equipment industry average (5.1x).
How is NuVasive forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NK8's forecast earnings growth (61.2% per year) is above the savings rate (0.2%).
Earnings vs Market: NK8's earnings (61.2% per year) are forecast to grow faster than the German market (22.5% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: NK8's revenue (10.5% per year) is forecast to grow faster than the German market (5.7% per year).
High Growth Revenue: NK8's revenue (10.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NK8's Return on Equity is forecast to be low in 3 years time (13.5%).
How has NuVasive performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NK8 has high quality earnings.
Growing Profit Margin: NK8's current net profit margins (5.3%) are higher than last year (4.4%).
Past Earnings Growth Analysis
Earnings Trend: NK8's earnings have grown by 1.1% per year over the past 5 years.
Accelerating Growth: NK8's earnings growth over the past year (24.7%) exceeds its 5-year average (1.1% per year).
Earnings vs Industry: NK8 earnings growth over the past year (24.7%) exceeded the Medical Equipment industry 8.2%.
Return on Equity
High ROE: NK8's Return on Equity (6.9%) is considered low.
How is NuVasive's financial position?
Financial Position Analysis
Short Term Liabilities: NK8's short term assets ($1.1B) exceed its short term liabilities ($782.1M).
Long Term Liabilities: NK8's short term assets ($1.1B) exceed its long term liabilities ($552.2M).
Debt to Equity History and Analysis
Debt Level: NK8's debt to equity ratio (111.7%) is considered high.
Reducing Debt: NK8's debt to equity ratio has increased from 54.9% to 111.7% over the past 5 years.
Debt Coverage: NK8's debt is well covered by operating cash flow (21.8%).
Interest Coverage: NK8's interest payments on its debt are well covered by EBIT (3.2x coverage).
What is NuVasive's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NK8's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NK8's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NK8's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NK8's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NK8's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chris Barry (46yo)
Mr. J. Christopher Barry serves as CEO and Director of NuVasive, Inc. since November 5, 218. Mr. Barry served commercial and leadership roles at Covidien. He has extensive experience as an innovative globa ...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD5.43M) is above average for companies of similar size in the German market ($USD2.40M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
|CEO & Director||1.58yrs||US$5.43m||0.019% $535.2k|
|Senior VP||2.42yrs||US$1.14m||0.020% $561.0k|
|Executive VP & CFO||0.42yr||no data||no data|
|Senior Vice President of Global Operations||0.50yr||no data||no data|
|Chief Information Officer||4.83yrs||no data||no data|
|Vice President of Internal & External Affairs||no data||no data||no data|
|Senior Vice President of Strategy & Corporate Development||0.50yr||no data||no data|
|Chief Human Resources Officer||1.42yrs||no data||0.013% $371.5k|
|Managing Director of DACH||6.5yrs||no data||no data|
Experienced Management: NK8's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
|CEO & Director||1.58yrs||US$5.43m||0.019% $535.2k|
|Independent Director||2.33yrs||US$230.06k||no data|
|Independent Director||4.33yrs||US$230.06k||no data|
|Independent Director||5yrs||US$250.06k||no data|
|Chairman of the Board||5.25yrs||US$830.06k||0.43% $12.0m|
|Independent Director||1.67yrs||US$230.06k||0.0027% $73.6k|
|Independent Director||4.92yrs||US$250.06k||no data|
|Independent Lead Director||2.08yrs||US$255.06k||0.018% $498.5k|
|Independent Director||6.08yrs||US$240.06k||no data|
Experienced Board: NK8's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
NuVasive, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: NuVasive, Inc.
- Ticker: NK8
- Exchange: DB
- Founded: 1997
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$3.148b
- Listing Market Cap: US$2.779b
- Shares outstanding: 51.25m
- Website: https://www.nuvasive.com
Number of Employees
- NuVasive, Inc.
- 7475 Lusk Boulevard
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NUVA||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||May 2004|
|NK8||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 2004|
|NUVA *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||May 2004|
NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company’s principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprises products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine to perform restorative and fusion procedures in a minimally disruptive fashion. The company’s biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty and gel. Its IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, it offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and Precice, a limb lengthening system. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/05 09:27|
|End of Day Share Price||2020/06/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.